Botulinum toxin type B improves the speed of reaching in children with cerebral palsy and arm dystonia: An open-label, dose-escalation pilot study

Journal of Child Neurology

Volumn 22, Issue 1, 2007, Pages 116-122

  Sanger, Terence D ^a   Kukke, Sahana N ^a   Sherman Levine, Sara ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Botulinum toxin; Cerebral palsy; Dystonia

Indexed keywords

BACLOFEN; BOTULINUM TOXIN B; TRIHEXYPHENIDYL;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARM MOVEMENT; ARTICLE; BICEPS BRACHII MUSCLE; CEREBRAL PALSY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DYSTONIA; HUMAN; LEUKOMALACIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE; VELOCITY;

ADOLESCENT; ARM; BOTULINUM TOXINS; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; CLINICAL PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSTONIC DISORDERS; FEMALE; HUMANS; MALE; MOVEMENT; NEUROMUSCULAR AGENTS; PILOT PROJECTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34249860815     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/0883073807299975     Document Type: Article

References (50)

1. Gormley ME, Gaebler-Spira D., Delgado MR Use of botulinum toxin type A in pediatric patients with cerebral palsy: A three-center retrospective chart review. J Child Neurol. 2001; 16: 113-118.
2. Graham HK, Aoki KR, Autti-Ramo I., et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture. 2000; 11: 67-79.
3. Koman LA, Mooney JF III, Smith B., Goodman A., Mulvaney T. Management of cerebral palsy with botulinum-A toxin: Preliminary investigation. J Pediatr Orthop. 1993; 13: 489-495.
4. Koman LA, Mooney JF III, Smith BP, Goodman A., Mulvaney T. Management of spasticity in cerebral palsy with botulinum-A toxin: Report of a preliminary, randomized, double-blind trial. J Pediatr Orthop. 1994; 14: 299-303.
5. Koman LA, Mooney JF III, Smith BP, Walker F., Leon JM Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: A randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop. 2000; 20: 108-115.
6. Russman BS, Tilton A., Gormley ME Jr. Cerebral palsy: A rational approach to a treatment protocol, and the role of botulinum toxin in treatment. Muscle Nerve Suppl. 1997; 6: S181-S193.
7. Fehlings D., Rang M., Glazier J., Steele C. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr. 2000; 137: 331-337.
8. Fehlings D., Rang M., Glazier J., Steele C. Botulinum toxin type A injections in the spastic upper extremity of children with hemiplegia: child characteristics that predict a positive outcome. Eur J Neurol. 2001; 8 (suppl 5): 145-149.
9. Graham HK, Boyd RN, Fehlings D. Does intramuscular botulinum toxin A injection improve upper-limb function in children with hemiplegic cerebral palsy? Med J Aust. 2003; 178: 95-96.
10. Autti-Ramo I., Larsen A., Taimo A., von Wendt L. Management of the upper limb with botulinum toxin type A in children with spastic type cerebral palsy and acquired brain injury: Clinical implications. Eur J Neurol. 2001; 8 (suppl 5): 136-144.
11. Dressler D., Bigalke H., Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol. 2003; 250: 967-969.
12. Factor SA, Molho ES, Evans S., Feustel PJ Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord. 2005; 20: 1152-1160.
13. Dolly O. Synaptic transmission: Inhibition of neurotransmitter release by botulinum toxins. Headache. 2003; 43 (suppl 1): S16-S24.
14. Brin MF Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl. 1997; 6: S146-S168.
15. Pellizzari R., Rossetto O., Schiavo G., Montecucco C. Tetanus and botulinum neurotoxins: Mechanism of action and therapeutic uses. Philos Trans R Soc Lond B Biol Sci. 1999; 354: 259-268.
16. Turton K., Chaddock JA, Acharya KR Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci. 2002; 27: 552-558.
17. Baumann L., Black L. Botulinum toxin type B (Myobloc). Dermatol Surg. 2003; 29: 496-500.
18. Dressler D., Adib Saberi F. Botulinum toxin: Mechanisms of action. Eur Neurol. 2005; 53: 3-9.
19. Brashear A., Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999; 53: 1439-1446.
20. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999; 53: 1431-1438.
21. Foran PG, Mohammed N., Lisk GO, et al. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem. 2003; 278: 1363-1371.
22. Purkiss JR, Friis LM, Doward S., Quinn CP Clostridium botulinum neurotoxins act with a wide range of potencies on SH-SY5Y human neuroblastoma cells. Neurotoxicology. 2001; 22: 447-453.
23. Roger Aoki K. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon. 2002; 40: 923-928.
24. Flynn TC, Clark RE II. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: Rate of onset and radius of diffusion. Dermatol Surg. 2003; 29: 519-522.
25. Muthane UB, Panikar JN Botulinum toxins: Pharmacology and its current therapeutic evidence for use. Neurology India. 2003; 51: 455-460.
26. Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997; 49: 701-707.
27. Lew MF, Brashear A., Factor S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Neurology. 2000; 55 (12 suppl 5): S29-S35.
28. Truong DD, Cullis PA, O'Brien CF, Koller M., Villegas TP, Wallace JD BotB (botulinum toxin type B): Evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study). Mov Disord. 1997; 12: 772-775.
29. Tsui JK, Hayward M., Mak EK, Schulzer M. Botulinum toxin type B in the treatment of cervical dystonia: A pilot study. Neurology. 199 5; 45: 2109-2110.
30. Comella CL, Jankovic J., Shannon KM, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005; 65: 1423-1429.
31. Dressler D., Bigalke H. Botulinum toxin type B de novo therapy of cervical dystonia: Frequency of antibody induced therapy failure. J Neurol. 2005; 252: 904-907.
32. Costa J., Espirito-Santo C., Borges A., et al. Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev. 2005 (1): CD004315.
33. Brashear A., McAfee AL, Kuhn ER, Ambrosius WT Treatment with botulinum toxin type B for upper-limb spasticity. Arch Phys Med Rehabil. 2003; 84: 103-107.
34. Brashear A., McAfee AL, Kuhn ER, Fyffe J. Botulinum toxin type B in upper-limb poststroke spasticity: A double-blind, placebo-controlled trial. Arch Phys Med Rehabil. 2004; 85: 705-709.
35. Wan XH, Vuong KD, Jankovic J. Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms. Chin Med Sci J. 2005; 20: 44-47.
36. Racette BA, Lopate G., Good L., Sagitto S., Perlmutter JS Ptosis as a remote effect of therapeutic botulinum toxin B injection. Neurology. 2002; 59: 1445-1447.
37. Tintner R., Gross R., Winzer UF, Smalky KA, Jankovic J. Autonomic function after botulinum toxin type A or B: A double-blind, randomized trial. Neurology. 2005; 65: 765-767.
38. Dubow J., Kim A., Leikin J., Cumpston K., Bryant S., Rezak M. Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections. Mov Disord. 2005; 20: 877-880.
39. Dressler D., Benecke R. Autonomic side effects of botulinum toxin type B therapy. Adv Neurol. 2004; 94: 315-320.
40. Baumann LS, Halem ML Systemic adverse effects after botulinum toxin type B (myobloc) injections for the treatment of palmar hyperhidrosis. Arch Dermatol. 2003; 139: 226-227.
41. Comella CL, Leurgans S., Wuu J., Stebbins GT, Chmura T. Rating scales for dystonia: A multicenter assessment. Mov Disord. 2003; 18: 303-312.
42. Martinez-Martin P., Gil-Nagel A., Gracia LM, Gomez JB, Martinez-Sarries J., Bermejo F. Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord. 1994; 9: 76-83.
43. Richards M., Marder K., Cote L., Mayeux R. Interrater reliability of the Unified Parkinson's Disease Rating Scale motor examination. Mov Disord. 1994; 9: 89-91.
44. Burke RE, Fahn S., Marsden CD, Bressman SB, Moskowitz C., Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology. 1985; 35: 73-77.
45. Haas BM, Bergstrom E., Jamous A., Bennie A. The inter rater reliability of the original and of the modified Ashworth scale for the assessment of spasticity in patients with spinal cord injury. Spinal Cord. 1996; 34: 560-564.
46. Bohannon RW, Smith MB Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987; 67: 206-207.
47. Sloan RL, Sinclair E., Thompson J., Taylor S., Pentland B. Interrater reliability of the modified Ashworth Scale for spasticity in hemiplegic patients. Int J Rehabil Res. 1992; 15: 158-161.
48. Blackburn M., van Vliet P., Mockett SP Reliability of measurements obtained with the modified Ashworth scale in the lower extremities of people with stroke. Phys Ther. 2002; 82: 25-34.
49. Varni JW, Seid M., Knight TS, Uzark K., Szer IS The PedsQL 4.0 Generic Core Scales: Sensitivity, responsiveness, and impact on clinical decision-making. J Behav Med. 2002; 25: 175-193.
50. Varni JW, Seid M., Kurtin PS PedsQL 4.0: Reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001; 39: 800-812.